Newtech Resources WKN 157768
Seite 1 von 1 Neuester Beitrag: 20.05.04 16:46 | ||||
| Eröffnet am: | 17.03.04 21:31 | von: ds99 | Anzahl Beiträge: | 18 |
| Neuester Beitrag: | 20.05.04 16:46 | von: KINI | Leser gesamt: | 3.678 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Es handelt sich wohl hier um ein Börsenmäntelchen das Formen zeigt, nun ich kenne diesen Wert selbst nicht, bin im WO-Board darauf aufmerksam geworden, vielleicht hat hier jemand Infos.
Gruß
ds99
Taxe Volumen
0,2 -
Verkauf Orders
Limit Stücke
0,2 3.500
0,23 14.000
0,25 15.000
0,3 42.950
0,36 375
angeblich stehen News an, na mal sehen wie es an der OTCBB läuft, folgendes Zitat aus einem WO-Thread:
#1668 von SoWhat 26.03.04 13:13:11 Beitrag Nr.: 12.561.789 12561789
Dieses Posting: versenden | melden | drucken | Antwort schreiben
Für Neugierige, die vielleicht nicht wissen worum es geht nochmal ein Posting von mir aus einem anderen Thread:
#1 von SoWhat 12.02.04 09:03:31 Beitrag Nr.: 12.128.064 12128064
Dieses Posting: versenden | melden | drucken | Antwort schreiben NEWTECH RESOURCES LTD
Guten Morgen,
einige kennen den Stock vielleicht schon. Ich verfolge ihn seit September. Es ist eine Hülle, die Company hat bisher nichts vorzuweisen. Sie reporten Pflichtgemäss. Ein Deal ist Ende letzten Jahres geplatzt und so stand das Unternehmen unter Druck etwas Neues zu finden. Nach meinen Kenntnissen waren zwei Deals vorbereitet, wobei sich nun abzeichnet, dass einer nun endgültig besiegelt wird. Wann dies genau sein wird weiss ich nicht, aber die Gerüchte verdichten sich immer mehr, dass es ziemlich bald eine News dbzgl. geben wird. Sobald die Nachricht dazu da ist, rechne ich mit einem Anstieg auf USD 0,50 und dann Richtung einen Dollar und weiter.
Drüben sickert es immer mehr durch, dass was ansteht.
Risiko bei 10000 Stück ca. 1500 Euro
Chance bei 10000 Stück ca. 5000 Euro bis Ende offen
Die Aktie mit der WKN 157768 gibts auch in Berlin.
ES HANDELT SICH UM EINE SPEKULATION, DIE IM SCHLIMMSTEN FALL ZU EINEM TOTALVERLUST FÜHREN KANN.
----------------
Aktie mittlerweile auch in Ffm gelistet. Warum wohl?
Good luck
sowhat
kann das einer bestätigen oder nur Push....?
Gruß
ds99
VANCOUVER, BRITISH COLUMBIA, Mar 26, 2004 (CCNMatthews via COMTEX) -- Newtech Resources Ltd. (" Newtech" ) (OTCBB: NTHR)(Berlin: NWE Security No. 157768) today announced that it has executed a letter of intent with Dr. Jyoti Ghosh and German Pharmaceuticals Limited to negotiate to acquire an exclusive worldwide license (excluding India and Germany) to Finance Production and market the Arogya II compound developed for the treatment of diabetes mellitus type II in exchange for a usage license fee and a royalty fee on units of the Arogya II compound sold. The letter of intent also entitles Newtech to a right of first refusal in respect to acquiring the same Rights relating to any other formulations Dr. Ghosh or German Pharmaceuticals might currently offer or develop in the future.
Diabetes mellitus is a chronic disease that requires long-term medical attention both to limit the development of its devastating complications and to manage them when they do occur. Type II diabetes typically occurs in individuals older than 40 years who have a family history of diabetes and is characterized by peripheral insulin resistance with an insulin-secreatary defect that varies in severity. These defects lead to increased hepatic gluconeogenesis, which produces fasting hyperglycemia. Most patients (90%) who develop type II diabetes are obese, and obesity itself is associated with insulin resistance, which in turn worsens the diabetic state.
The morbidity and mortality associated with diabetes are related to short and long-term complications. These complications include hypoglycemia and hyperglycemia, increased risk of infections, micro vascular complications (i.e., retinopathy, nephropathy), neuropathic complications, and macro vascular disease. Diabetes is the major cause of blindness in adults aged 20-74 years, as well as the leading cause of nontraumatic lower-extremity amputation and end-stage renal disease. According to the World Health Organization there were 177 million diabetes patients worldwide in 2000. Indications are that this number has since grown due to increased life expectancy (the prevalence of diabetes increases with age) and the relatively recent phenomena of childhood obesity.
Dr. Ghosh`s Arogya II compound is formed from an unique combination of phyto pharmaceutical and Soluble Minerals Supplement, all of natural origin, that have been used to effectively manage the disease. Arogya II does not produce any side effects.
Newtech, Dr. Ghosh and German Pharmaceuticals expect to sign the agreement upon the successful completion of negotiations and due diligence inquiries by all parties.
Newtech is a public company; its common shares trade on the OTCBB under the ticker symbol " NTHR" and on the Berlin Stock Exchange under the symbol " NWE" .
A number of statements contained in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. These forward looking statements involve a number of risks and uncertainties, including timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results of Newtech may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. Newtech encourages the public to read the information provided here in conjunction with its most recent filings on Form 10KSB and Form 10QSB. Newtech`s public filings may be viewed at www.sec.gov.
CONTACT: Newtech Resources Ltd.
Ross Wilmot
President
(604) 602-1717
Email: rwilmot@ipm.bc.ca
Copyright (C) 2004, CCNMatthews. All rights reserved.
NEWS RELEASE TRANSMITTED BY CCNMatthews -0-
INDUSTRY KEYWORD: MTC - Medical & Biological Technology
SUBJECT CODE: BFC - BUSINESS CONTRACTS
STOCK SYMBOLS: [(otc bulletin board:nthr)] [(berlin:nwe)]
ein schönes Teil hast Du da ausgegraben - richtiger Zeitpunkt , jetzt schon super gelaufen und wird wohl noch mehr wenn die 0,2 fallen.
Hut ab !
Gruß
leo
bei dieser Aktie weiß man mal wieder, das man nichts weiß......( Dr. Jyoti Ghosh )
da bin ich gespannt wie es weitergeht
Gruß
ds99
Das Risiko nach unten ist nun um einiges geringer ;-)
Gruß
ds99
Volumen Taxe
- 0,14
Kauf Orders
Stücke Limit
63.000 0,14
2.150 0,125
30.000 0,12
- -
- -
Weitere: 0
Best Ask
Taxe Volumen
0,155 -
Verkauf Orders
Limit Stücke
0,179 15.000
0,195 11.000
0,29 5.000
0,3 55.000
0,36 375
Gruß
ds99
gepaart mit dem Börsenmäntelchen.....warten wir es mal ab
&a=157768&b=0&banner_ref=HASH(0x9e5273c)&zeitraum=5&ind_volume=ON&zoom.x=0&ISSE=v2-512204-695754-2570-146515&v2-512204-695754-2570-146515=ARRAY(0x9e66da8)&zeitbis=&bname=&bis=1083042609.14102&cookies=HASH(0x9e594f4)&req_host=ARRAY(0x9fe830c)&zeitvon=0&von=0 "ariva.de")
Gruß
ds99
Newtech Creates Advisory Board
VANCOUVER, BRITISH COLUMBIA, Apr 30, 2004 (CCNMatthews via COMTEX) -- Newtech Resources Ltd. ("Newtech") (OTCBB: NTHR)(Berlin: NWE Security No. 157768) today is pleased to announce that it has created an advisory board consisting of two individuals who will assist the company with future financing and marketing.
Joining the Newtech team is Mr. Kjell Jagalid, of Zurich, Switzerland, and Mr. Rick Yanus of San Diego, California.
Kjell Jagelid of Zurich Switzerland has over twenty-five years experience in international management with negotiations in engineering, financial, banking, mergers and business agreements. In addition, Kjell has over 10 years public company experience in the United States and Europe. His network of business contacts extends internationally. Kjell has also filed over 15 patents, which have been successfully used worldwide in the mechanical and construction industries. Kjell has an Equivalent Bachelors Degree in Finance at PHF Goteborg, Sweden and an Equivalent Bachelors Degree, (Civil and Mechanical Engineering) at GTI, Sweden. Kjell is fluent in English, Swedish, (all Scandinavian languages) and proficient in German.
Rick Yanus has over twenty years experience in the pharmaceutical industry. With a background as a clinical pharmacist, Rick specialized in diabetes by also becoming a board certified diabetes educator (CDE). Rick's experience in the sales and marketing of key diabetes medications includes some of the most successful drugs ever launched for diabetes: Glucophage, Avandia, Rezulin and Diabeta. Rick was involved in the strategic planning and launch of other key medications: Lipitor, Plavix, Avapro, Vicodin and twelve other medications. Rick created the newsletter DiaBeat, in 1997 to help educate patients and allied health professionals on key topics in diabetes and co-authored a text for educating pharmacists in the United States on diabetes complications. Rick has an MBA in marketing from Southern New Hampshire University as well as a BS-Pharmacy from Albany College of Pharmacy in Albany, NY. Rick is a registered pharmacist (RPh) in both New York and New Hampshire.
Newtech is a public company; its common shares trade on the OTCBB under the ticker symbol "NTHR" and on the Berlin Stock Exchange under the symbol "NWE".
A number of statements contained in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. These forward looking statements involve a number of risks and uncertainties, including timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results of Newtech may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. Newtech encourages the public to read the information provided here in conjunction with its most recent filings on Form 10KSB and Form 10QSB. Newtech's public filings may be viewed at www.sec.gov.
CONTACT: Newtech Resources Ltd.
Ross Wilmot
President
(604) 602 1717
Email: rwilmot@ipm.bc.ca
Copyright (C) 2004, CCNMatthews. All rights reserved.